Extracorporeal Membrane Oxygenation (ECMO) Machine Market Size & Analysis Report, By Modality (Veno-Arterial, Veno-Venous, Arterio-Venous), By Application, By Region, And Segment Forecasts, 2018 - 2025

Industry Insights

The global Extracorporeal Membrane Oxygenation (ECMO) Machine market size was valued at USD 246.5 million in 2016 and is expected to grow at CAGR of 4.3% over the forecast period. The major factors boosting growth are the rising incidences of Chronic Obstructive Pulmonary Disorder (COPD), and surging prevalence of cardiopulmonary diseases and respiratory failures.

ECMO machine treatment is used most in patients suffering from cardiopulmonary failure or cardiogenic shock followed by patients suffering from respiratory failure. This treatment option is also used for patients undergoing a heart transplant or a lung transplant. 

According to data recorded by the American Lung Association (ALA), in 2013, COPD was recorded to be the third largest cause of death across the U.S. In addition, over 24.0 million individuals are estimated to remain undiagnosed in the U.S. and 11.0 million diagnosed for COPD.

Since the incorporation of ECMO in the treatment and management of the swine flu epidemic of 2009, ECMO centers have been on the rise. Increased survival rate of swine flu patients treated with ECMO led to an increase in the number of centers to 298 in 2015 from 148 in 2008.

Also, the increasing adoption of unhealthy lifestyles, such as rise in the total tobacco consumption level among both, females and males and further development of lifestyle disorders are augmenting the incidence rate of COPD. Extracorporeal Membrane Oxygenation machines are gaining popularity in the hospital and healthcare systems due to the rising trend of its application during cases of respiratory disorders.

The Extracorporeal Membrane Oxygenation machines are used in cases of cardiac failure to facilitate auxiliary oxygen support system. These machines are frequently used in patients suffering from respiratory conditions and also in neonates and pediatric patients. The estimated growth of these machines can be attributed to the critical nature of the target population consisting of neonates and pediatric patients.

Applications Insights

As per applications, the market is segmented into Extracorporeal Cardiopulmonary Resuscitation (ECPR), respiratory and cardiac. The segments are further segmented on the basis of who is using the set up into adult application, neonate and pediatric. The segment dominating the market in 2016 with about 42.0% of the industry share is respiratory based ECMO.

In case of respiratory illnesses, ECMOs serve as artificial lungs, thus playing a crucial role in supporting pulmonary function. According to a report published in January 2016 by the Extracorporeal Life Support Organization, a total of 45,035 patients globally suffer from respiratory illnesses and require Extracorporeal Membrane Oxygenation therapy. Thus, on the basis of procedure volume, the respiratory segment dominates the extracorporeal membrane oxygenation market.

In the respiratory segment the adult segment dominated the market revenue in 2016, this is attributed to the increased disease prevalence of COPD and associated cardiopulmonary diseases in this segment. According to the volume analysis the neonates segment dominated the respiratory segment of the market in 2016.

The ECMO systems are used to treat severe cardiac conditions such as cardiac shock or arrest wherein the ECMO machine serves as an artificial heart. According to the report published by the Extracorporeal Life Support Organization, in January 2016, there were overall 22,140 patients globally who suffered from cardiac illness and required ECMO.

Amongst the cardiac segment most of the patients treated with ECMO belonged to the pediatric age group till 2015, after that there is a shit in the procedure volume toward adult patients from 2016. By 2025, it is estimated that adult population will hold the largest procedure volume amongst the cardiac segment. This increase in cardiac procedure volume for adults can be attributed to increasing disease prevalence of cardiopulmonary diseases. According to the revenue, the adult patient population holds the largest market share amongst the cardiac application segment of the market.

Extracorporeal cardiopulmonary resuscitation is also known as rescue therapy. It is used to treat patients suffering from in-hospital cardiac arrest as well as out-hospital cardiac arrest.Around 6,421 people globally went through extracorporeal cardiopulmonary resuscitation, according to the report published by Extracorporeal Life Support Organization in January 2016.

ECMO is recommended as a treatment option for neonates who are unresponsive towards high frequency ventilation. The veno-arterial ECMO machine is used in most cases with a greater survival rate as compared to veno-venous ECMO. The number of neonates treated with ECMO for respiratory diseases was found to be highest in 2016, followed by adult patients and lastly by pediatric patients.

The increasing demand for the ECMO systems is majorly attributed to rising number of patients with chronic respiratory conditions like COPD, emphysema and chronic bronchitis combined with a trend of growing awareness about health disorders. As per the U.S. National Center for Health Statistics, more than 8.7 million individuals suffered from chronic bronchitis and 3.4 million individuals suffered from emphysema in the year 2014.

Modality Insights

The segmentation of the key modalities is done on the basis of the different setups that are provided by the ECMO circuit such as arterio-venous, veno-arterial and veno-venous. They are used to provide hemodynamic support and to facilitate gaseous exchange in patients with cardiac or respiratory failure.

Both gas exchange support and hemodynamic support is provided by the veno-arterial ECMO system. It majorly works by passing the blood flow from the patients’ heart and lungs to the ECMO circuit. The veno-venous ECMO system on the other hand facilitates sole gas exchange support in which the blood is made to return to the heart prior to pulmonary circulation. According to the U.S. National Institute of Health (NIH), combination of veno-venous and veno-arterial is used in specific cases such as cardiogenic shock. 

The veno-arterial segment has the largest volume in the market in terms of modality, followed by veno-venous and arterio-venous. The volume of veno-arterial segment is high due to the increasing use of treatment in patients suffering from cardiovascular collapse. Veno-arterial ECMO can be used for the treatment/management of decreased cardiac output and tissue hypoperfusion which results in cardiogenic shock. This can act as a trigger for myocardial infraction or chronic ischemia.

Regional Insights

The major regions in this market are North America, Europe, Asia Pacific, Latin America and MEA. North America has grown considerably in this segment majorly attributed to the well-developed primary, secondary and tertiary care hospitals combined with the reimbursement network, increasing awareness about the ECMO system facilitating their rapid adoption in the hospitals and favorable government funding.

The Asia Pacific region is expected to drive growth in the market. China is estimated to dominate the Asia Pacific market over the forecast period. The increasing disease prevalence of lung cancer is attributed to the growth of the market in China. Medical experts have estimated that by 2020, 700,000 deaths annually will be due to lung cancer. The major causes of lung cancer in China include air population and tobacco related illnesses.

ECMO Market Share Insights

Some key players operating in the ECMO market include MAQUET Holding B. V. & Co. KG, Microport Scientific Corporation, Medos Medizintechnik AG, Sorin Group, Medtronic, Plc., Terumo Cardiovascular Systems Corporation, and Nipro Medical Corporation. The major strategic initiatives adopted by the companies in this vertical are technological advancements in the existing portfolio and new product development.

Refinements in the technology presently in use was made by Terumo Cardiovascular Systems Corporation during the production of CAPIOX FX Oxygenator. This system is expected to help in increasing the blood rate and offer complete control over the entire process.

For example, Medtronic Plc designed Minimax Plus Oxygen System for patients from wide ranging age groups such as from neonates to children, with features such as venous air director and low arterial port, which are integrated in the system to increase the safety levels and performance.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2013 to 2025. For the purpose of this study, Grand View Research has segmented the global extracorporeal membrane oxygenation machine market report on the basis of modality, application, and region:

• Modality Outlook (Revenue, USD Million, 2013 - 2025)

  • Veno-Arterial

  • Veno-Venous

  • Arterio-Venous

• Application Outlook (Revenue, USD Million, 2013 - 2025)

  • Respiratory

    • Neonates

    • Pediatric

    • Adult

  • Cardiac

    • Neonates

    • Pediatric

    • Adult

  • Extracorporeal Cardiopulmonary Resuscitation (ECPR)

    • Neonates

    • Pediatric

    • Adult

• Regional Outlook (Revenue, USD Million, 2013 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa

    • Saudi Arabia